Jazz Pharmaceuticals plcNASDAQ: JAZZ

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

· Issued by Jazz Pharmaceuticals plc via PR Newswire

Summary by 6ix AI

Jazz Pharmaceuticals plc, a biopharma company developing medicines for people with rare diseases, said its management will take part in fireside chats (informal on-stage interviews) at three investor conferences, starting November 17, 2026.

Key details

  • Jefferies London Global Healthcare Conference: Tuesday, November 17, 2026, at 8:00 a.m. ET.
  • Piper Sandler 38th Annual Healthcare Conference: Wednesday, December 2, 2026, at 8:00 a.m. ET.
  • Citi's 2026 Global Healthcare Conference: Wednesday, December 2, 2026, at 3:00 p.m. ET.
  • Audio webcasts of the chats will be available in the Investors section of the Jazz Pharmaceuticals website, with replays archived for 30 days.

6ix AI wrote this summary from the release below and checked it against the release.

DUBLIN, Nov. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:

  • Jefferies London Global Healthcare Conference on Tuesday, November 17, 2026, at 8:00 a.m. ET
  • Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026, at 8:00 a.m. ET
  • Citi's 2026 Global Healthcare Conference on Wednesday, December 2, 2026, at 3:00 p.m. ET

Audio webcasts of the fireside chats will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts

Investors:
[email protected]
Ireland +353 1 634 7800
U.S. +1 650 496 2717

Media:
[email protected]
Ireland +353 1 637 2141
U.S. +1 215 867 4948

SOURCE Jazz Pharmaceuticals plc

View original source (PR Newswire)Jazz Pharmaceuticals plc on 6ix

Story so far

Earlier from Jazz Pharmaceuticals

All Jazz Pharmaceuticals news releases